Your search matched 16 results
The 2021 Health Trends Series | Perspectives
As we worked with providers, innovators and experts around the world to understand the trends most likely to drive change in life science clinical and commercial engagement, twenty quickly stood out.
In this Fierce Pharma article, Leigh Householder at Syneos Health, shares: “It really is a pivot point.
The U.S. | Blog
Democrats have revealed that the next major legislative package—colloquially known as the infrastructure package—will likely include provisions to lower prescription drug prices.
At Adexchanger’s recent Identity Day, part of a virtual series about trends in data-driven marketing, one hot topic was the announcement of the end of third-party cookies from Google.
COVID-19 has changed the way we think, live, and work.
eMarketer’s latest numbers on Pharma’s digital ad spend are in, and the word of the day is growth.
For more than 30 years, AnswerSuite has been fueling the biopharmaceutical industry with syndicated data and custom HCP insights that help deepen relationships and optimize the value of the total promotional mix.
Digital assistants are increasingly finding their way into most homes and as a result, voice searches are changing the way brands think of SEO.
Trends Changing Healthcare | Blog
Live from Cannes Lions Health: Andrea Bell, Director of Insight and Executive Editor at WGSN, shared her perspective on the top five trends changing healthcare.
Recently, the World Health Organization classified “video game addiction” as a mental health disorder.
Everyone feels differently about weight, weight gain, and health—some welcome interventions while others bristle at them.
Seasoned Talent to Drive Expansion of Solutions at the Intersection of Value and Policy
While federal drug pricing reform in the Build Back Better Act (BBBA) is stalled at the Senate, states are taking the issue into their own hands.
There are three potential solutions for pharma, device, or DTx marketers to consider based on trends we’ll see in the year ahead.
How will the Institute for Clinical and Economic Review (ICER) reconcile the tug-of-war between the promise and uncertainty in valuing gene therapies?